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In Brief
Lymphocyte Activation Gene-3 (LAG-3) is
a checkpoint molecule that has been
targeted alongside programmed cell
death (PD-1) for immunotherapy. Here,
Rudd et al. demonstrate inhibition of
glycogen synthase kinase-3 to control
LAG-3 expression and that its
combination with anti-LAG-3 antibody
enhances T cell responses against
tumors, causing tumor regression.
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Immune checkpoint blockade using antibodies
against negative co-receptors such as cytolytic
T cell antigen-4 (CTLA-4) and programmed cell
death-1 (PD-1) has seen much success treating can-
cer. However, most patients are still not cured,
underscoring the need for improved treatments and
the possible development of small molecule inhibi-
tors (SMIs) for improved immunotherapy. We previ-
ously showed that glycogen synthase kinase (GSK)-
3a/b is a central regulator of PD-1 expression, where
GSK-3 inhibition down-regulates PD-1 and enhances
CD8+ cytolytic T cell (CTL) function, reducing viral in-
fections and tumor growth. Here, we demonstrate
that GSK-3 also negatively regulates Lymphocyte
Activation Gene-3 (LAG-3) expression on CD4+ and
CD8+ T cells. GSK-3 SMIs are more effective than
LAG-3 blockade alone in suppressing B16melanoma
growth, while their combination resulted in enhanced
tumor clearance. This was linked to increased
expression of the transcription factor, Tbet, which
bound the LAG-3 promoter, inhibiting its transcrip-
tion, and to increased granzyme B and interferon-
g1 expression. Overall, we describe a small molecule
approach to inhibit LAG-3, resulting in enhanced
anti-tumor immunity.INTRODUCTION
Immunecheckpointblockade (ICB) isapromisingapproach for the
treatment of cancer. The approach involves the blockade of nega-
tive co-receptors on T cells such as cytolytic T cell antigen-4
(CTLA-4) and programmed cell death-1 (PD-1). PD-1 expression
on tumor-infiltrating CD8+ T cells correlateswith impaired function
(Ahmadzadeh et al., 2009), while PD-L1 expression on tumor cells
facilitates their escape from the immune response (Iwai et al.,
2002). ICB reverses T cell exhaustion and restores T cell function-Cell Rep
This is an open access article undality (Freeman et al., 2006; Wherry, 2011). The cancer treatment
drug nivolumab (Opdivo) against PD-1 was approved as a first-
line treatment for advanced melanoma and has been used alone,
and in combination with ipilimumab (Yervoy), an anti-CTLA-4 anti-
body (Ab) resulting in high response rates (Hodi et al., 2010;
Sharma et al., 2011; Wolchok et al., 2013). However, despite this
success, many patients are still not cured and may suffer im-
mune-related adverse events (irAEs). This poor prognosis con-
tinues to highlight a need to develop novel clinical interventions.
In this context, we have identified the enzyme glycogen synthase
kinase-3 (GSK-3) as a major nexus in the control of PD-1 expres-
sion on T cells (Taylor et al., 2016). We also showed that small
molecule inhibitors (SMIs) of GSK-3 can suppress tumor growth
in amanner comparable to PD-1 Ab blockade (Taylor et al., 2018).
Among the expanding numbers of inhibitory co-receptors
on T cells are Lymphocyte Activation Gene-3 (LAG-3), T cell im-
munoreceptor with immunoglobulin (Ig) and ITIM domains
(TIGIT), CD244 (2B4), T cell Ig and mucin-domain containing-3
(TIM-3), CD160, killer-cell lectin like receptor G1 (KLRG-1), and
B and T lymphocyte attenuator (BTLA-4) (Baumeister et al.,
2016). LAG-3 is an activation antigen that negatively regulates
T cells (Workman et al., 2004; Workman and Vignali, 2003). It is
a cell-surface molecule initially discovered on natural killer (NK)
cells (Triebel et al., 1990) and then on activated T cells (Huard
et al., 1994), B cells, and plasmacytoid dendritic cells (Workman
et al., 2009). Furthermore, LAG-3 is a member of the Ig super-
family, containing four Ig loops, with structural homology to
CD4. Unlike CD4, the membrane-distal IgG domain contains
an extra loop region that appears important for binding to major
histocompatibility complex class II (MHC class II) molecules
(Triebel et al., 1990). Aside from MHC class II antigens, fibrin-
ogen-like protein-1 is a major immune inhibitory ligand of
LAG-3 (Wang et al., 2019). Studies in LAG-3 knockout mice
have demonstrated an inhibitory role for LAG-3 in controlling
both CD4 and CD8 T cell proliferation in vitro and in vivo
(Workman et al., 2004). This negative effect on T cell function
is exerted through a poorly understood but unique amino acid
sequence (KIEELE) in the intracellular domain (Workman et al.,
2002). Importantly, LAG-3 and PD-1 are co-expressed at high
levels in tumor-infiltrating lymphocytes (TILs) from murine
ovarian tumor and EG7-bearing mice, and blockade of bothorts 30, 2075–2082, February 18, 2020 ª 2020 The Author(s). 2075
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molecules enhances CD8+ effector T cell frequency and func-
tion, thus enhancing anti-tumor immunity (Andrews et al.,
2017; Huang et al., 2015; Woo et al., 2012).
We originally demonstrated that the inhibition of serine/threo-
nine kinase GSK-3 downregulates PD-1 expression, which en-
hances T cell responses against viral infections (Taylor et al.,
2016, 2018). There are two ubiquitously expressed and highly
conserved isoforms of GSK-3, GSK-3a and GSK-3b, which
have shared and distinct substrates, aswell as functional effects.
Both forms have been implicated in processes ranging from
glycogen metabolism to gene transcription, apoptosis, and
microtubule stability. The notable aspect of GSK-3 is that it is
constitutively active in resting T cells (Embi et al., 1980; Wood-
gett, 1990) and is inhibited by receptor-induced activation sig-
nals (Woodgett, 2001).
Our findings also showed that GSK-3 inhibition operated
primarily via a reduction in PD-1 transcription on CD8+ T cells
(Taylor et al., 2016, 2018). We further showed that SMIs against
GSK-3 are as effective as anti-PD-1 Abs in restricting B16 and
EL-4 tumor growth in mice (Taylor et al., 2018). In this article,
we demonstrate that GSK-3SMIs and siRNAs can also
downregulate LAG-3 expression on T cells and that combination
therapy of SMIs with LAG-3 can significantly enhance the clear-
ance of tumors in mice.
RESULTS AND DISCUSSION
Small Molecule Inhibition of GSK-3 Downregulates PD-1
and LAG-3 in T Cells
We have previously shown that the inactivation of GSK-3a/b in-
creases Tbet expression for the downregulation of PD-1 expres-
sion (Taylor et al., 2016, 2018; Taylor and Rudd, 2017). By
contrast, we found no effects on the expression of other T cell re-
ceptors, including CD3, CD4, CD8, CD28, CTLA-4, CD44,
CD62L, TIM-3, CD3, BTLA, NKG2D, CD122, IL-2Ra, CD25,
CD69, FasL, and CD8 (Taylor et al., 2016). However, given that
Tbet can regulate the expression of multiple genes (Lazarevic
and Glimcher, 2011), we widened our survey of potential
GSK-3 targets. Of particular interest was the expression of other
inhibitory receptors (IRs). To this end, CD8+ OT-1 T cells were
stimulated with OVA257–264 (SIINFEKL) peptide in the presence
or absence of the GSK-3 SMI SB415286 over 7 days, during
which samples were assessed for LAG-3 expression using
flow cytometry and PCR analysis. As expected from previous
work (Taylor et al., 2016, 2018; Taylor and Rudd, 2017), the
OVA-induced upregulation of PD-1 was markedly reduced
by the presence of the GSK-3 SMI. Surprisingly, the expression
of LAG-3 was also downregulated by the presence of SMI,
while the expression of other IRs such as CTLA-4, BTLA-4,
and TIM-3 was unaffected (Figure 1A).
T cells isolated from wild-type C57BL/6 mice activated with
anti-CD3 showed an increase in LAG-3 expression that was
reduced by the presence of SB415286 (Figure 1B, left panel).
As expected, the level of LAG-3 expression on anti-CD3-acti-
vated Pdcd/ (PD-1-deficient) T cells was higher than seen on
control T cells, consistent with the inhibitory effect of PD-1 on
T cell activation. Nevertheless, SB415286 markedly reduced
LAG-3 levels on anti-CD3-activated Pdcd/ T cells (Figure 1B,2076 Cell Reports 30, 2075–2082, February 18, 2020right panel). These data showed that GSK-3 inactivation down-
regulates LAG3 independent of PD-1 expression.
We next assessed whether the suppression of LAG-3 expres-
sion was mediated at the level of transcription of LAG-3
throughout the 7-day time course, as seen by use of real-time
PCR (Figure 1C). The level and time course of the inhibition of
LAG-3 transcription was similar to that of PD-1, while CTLA-4
transcription was unaffected.
Moreover, different ATP-competitive inhibitors SB415286,
SB216763, and CHIR99021 had similar effects on both LAG-3
and PD-1 expression (Figure 1D). SB216763 has been reported
to have a preference for the GSK-3a isoform, whereas
CHIR99021 preferentially inhibits GSK-3b (Kaidanovich-Beilin
and Eldar-Finkelman, 2006). SB415286 competitively inhibits
both isoforms, with a preference for the b isoform (Coghlan
et al., 2000). In all cases, LAG-3 and PD-1 transcription levels
were reduced.
LAG-3 is also known for its role in regulating CD4+ T cell
function (Workman et al., 2002); therefore, the effect of SMI in
CD4+ T cells was investigated using OT-II transgenic mice.
CD4+ OT-II T cells were activated with OVA323–339 (ISQAVHAA-
HAEINEAGR) peptide in the presence or absence of SMI
for 7 days. Flow cytometry showed that GSK-3 inactivation
reduced expression of LAG-3 on CD4+ T cells (Figures S1A
and S1B). Similarly, inhibition of GSK-3 decreased LAG-3
expression on NK cells (defined as CD3NKp46+ cells)
(Figure S1C). Overall, our findings identified LAG-3 as a novel
target regulated by the inhibition of GSK-3 in CD4 and CD8+
T cells.
Anti-LAG-3 Treatment Combined with GSK-3 SMIs
In Vitro Enhances CD8+ T Cell Cytolytic Responses
Given that anti-LAG-3 and GSK-3 SMI treatment would not
be expected to block LAG-3, we next assessed whether they
cooperate to enhance antigen-specific CD8+ T cell cytolytic re-
sponses (Figure 2). CD8+ OT-I T cells were stimulated with
OVA257–264 for 5 days in the presence of anti-LAG-3 Ab at
different doses. After 5 days of activation, the killing of EL4
lymphoma target cells by cytolytic T cells (CTLs) using a lactate
dehydrogenase (LDH) release detection assay. EL4 cells were
pulsed with OVA peptide before the incubation to induce an
antigen-specific response. Non-pulsed EL4 cells were used as
a control for background killing. A trend was observed in which
anti-LAG-3 increased killing; however, this did not achieve sta-
tistical significance (Figure 2A). By contrast, the addition of
GSK-3 SMIs did increase in vitro OT-I killing, and the combina-
tion of GSK-3 SMIs and anti-LAG-3 increased the killing further
at statistically significant levels (Figure 2B). This was seen over
a range of target ratios and was generally better than the coop-
erativity seen with anti-PD-1 and anti-LAG-3 combination ther-
apy. Together, these data show that under conditions in which
anti-LAG-3 blockade alone has limited effects in unleashing
T cell responses against tumors, the inhibition of GSK-3, while
having an effect on its own, sensitizes T cells to be more respon-
sive to tumor antigens.
A similar cooperativity was observed when small interfering
RNAs (siRNAs) against the GSK-3a and GSK-3b isoforms
were used to knock down (KD) expression (Figure 2C). Naive
Figure 1. Inhibition of GSK-3 Downregulates PD-1 and LAG-3 on CD8+ T Cells
(A) OT-I CD8+ T cells stimulated with OVA peptide in the presence or absence of SB415286. Flow cytometric profiles. Green line, without SB415286; red line, with
SB415286.
(B) C57BL/6 (left) or PD-1-deficient (right) T cells stimulated with anti-CD3 in the presence or absence of SB415286. Flow cytometric profiles. Green line, without
SB415286; red line, with SB415286.
(C) Transcription of LAG-3 (left), PD-1 (middle), and CTLA-4 (right) in the presence or absence of SB415286.
(D) Downregulation of PD-1 and LAG-3 on OT-I CD8+ T cells in the presence of other GSK-3 inhibitors: SB216763 and CHIR99021.
Data are represented as mean ± SD based on triplicate values in individual experiments; data shown represent three independent experiments. Groups are
compared using unpaired t test. *p < 0.05, **p < 0.01, ***p < 0.001. ns, not significant.T cells were transfected before a 5-day activation period with
OVA-pulsed EL4 cells and then assessed for cytolytic function
using LDH release assays. siRNA treatment reduced GSK-3a
and GSK-3b protein substantially, as seen by flow cytometry
(Figure 2C, top panel), in which with the use of fluorescent
GFP-conjugated siRNAs, more than 80% of cells took up the
siRNAs. siRNAs to GSK-3 increased OT-I-mediated cytolysis
of EL4-OVA targets when compared with the scrambled
(Scrm) siRNA control (Figure 2C, bottom panel). This was signif-
icantly increased by the addition of anti-LAG-3 Ab. These data
again showed that the combination of GSK-3 inactivation and
anti-LAG-3 Ab therapy markedly increased the killing capacity
of CD8+ OT-I CTLs.Combined Treatment of Anti-LAG-3 Abwith GSK-3 SMIs
In Vivo Enhances CD8+ T Cell Cytolytic Responses
To assess whether the combination of anti-LAG-3 with GSK-3
inhibition was effective in limiting tumor growth, B16 tumor
cells tagged with luciferase were injected intravenously into
C57BL/6 mice and treated with the GSK-3 SMI SB415286, anti-
LAG-3, and/or anti-PD-1 (Figure 3). The optimal dose of
SB415286, LAG-3, and PD-1 was established at 200 mg/mouse/
treatment. SB415286 was administered every 2 days on six
occasions, beginning 7 days post-injection of tumor cells, with
the Ab given on four occasions (days 7, 10, 13, and 16). At days
10, 12, and 19, mice were injected intraperitoneally with luciferin
and scanned by IVIS Lumina imaging (Figure 3A; Figure S2).Cell Reports 30, 2075–2082, February 18, 2020 2077
Figure 2. LAG-3 Potentiates the CD8+ T Cell Cytolytic In Vitro Responses to GSK-3 Inhibition
(A) Cytolytic assay in response to OVA peptide in the presence of anti-LAG-3 at different concentrations.
(B) Cytolytic assay in response to GSK-3 inhibition combined with LAG-3 blockade.
(C) Flow cytometry profiles demonstrate siRNA uptake (upper left panel) using GFP-Scrm siRNA and KD of GSK-3 (gray line, upper right panel) in comparison to
Scrm (black line). Cytolytic assay (lower panel) of GSK-3 siRNA-transfected OT-I cells in the presence or absence of LAG-3 blockade.
Statistical analysis based on triplicate values in individual experiments showing means and SDs (unpaired t test). *p < 0.05, **p < 0.01, ***p < 0.001.Importantly, anti-LAG-3 treatment alone did not have a statisti-
cally significant effect on B16 tumor growth. Anti-PD-1 or
SB415286 treatment alone reduced the luciferase signal relative
to control at all time points. However, the combination of anti-
LAG-3 with SB415286 treatment was seen to be the most effec-
tive in decreasing tumor growth. As reported (Huang et al., 2015;
Zhang and Vignali, 2016), anti-LAG-3 plus anti-PD-1 also showed
a trend in cooperating to reduce tumor size (Figure 3A); however,
the combination of anti-LAG-3 and SB415286 was even more
effective than anti-LAG-3 plus anti-PD-1. The efficacy of anti-
LAG-3 with SB415286 treatment was observed by total flux mea-
surements and the percentage of mice showing complete tumor
clearance (Figure 3A, left panels). In both instances, the combina-
tion of anti-LAG-3 andGSK-3 inactivationwasmore effective than
anti-LAG-3 plus anti-PD-1.
The cooperativity between anti-LAG-3 and SB415286 was
particularly evident when we measured the complete loss of
tumor (Figure 3A, right histogram). In this representative
experiment, the combination was significantly more potent in
clearing the tumor (3/5 mice) when compared with the effects2078 Cell Reports 30, 2075–2082, February 18, 2020of anti-LAG-3 alone (0/5 mice) and SB415286 alone (1/5 mice).
While the synergistic effects of PD-1 and LAG-3 on T cell function
have been reported previously (Huang et al., 2015; Nguyen and
Ohashi, 2015; Okazaki et al., 2011), our findings show that
the combination of anti-LAG-3 plus GSK-3 inhibition is more
effective than this previously documented combination against
B16 melanoma. No direct effect of SB415286 on tumor cells
was observed as previously demonstrated by treating B16 tu-
mor-bearing Rag2/ mice (devoid of B and T cells) with
SB415286. Further, SB415286 had no obvious effect on tumor
growth in vitro (Taylor et al., 2018).
The presence of SB415286 alone increased the presence
of GZMB+CD8+CD3+ T cells and TNF+IFNg+CD3+CD8+ T cells
(Figure 3B), while anti-LAG-3 alone also increased GZMB+
T cells. However, the combination of anti-LAG-3 plus SB415286
or anti-LAG-3 plus PD-1 further increased the presence of
TNF+IFNg+CD3+CD8+ T cells and GZMB-expressing CD8+CD3+
TILs in accordance with the increased efficacy of tumor killing.
The combination of anti-LAG-3 with SB415286 was generally
more effective than anti-LAG-3 combined with anti-PD-1.
Figure 3. Combining GSK-3 Inhibition with Anti-LAG-3 Therapy Further Inhibits Pulmonary Metastasis of B16 Melanoma
(A) Luminescent image showing B16metastasis at day 19 with total flux values (in photons per second) depicted in the histogram in the middle. The histogram on
right shows the percentage of tumor-free animals at the end of the study on day 19 (n = 5).
(B) Anti-LAG-3 plus SB415286 increases the presence of granzymeB+CD8+CD3+ TILs (upper panel) and TNF+IFN+CD8+CD3+ TILs (lower panel), as measured by
flow cytometry (n = 5). GSK-3 inhibition of LAG-3 affects the PD-1+ T cell subset.
(C) Flow cytometry analysis of TILs from B16 tumors showing the downregulation of LAG-3 and PD-1 (n = 5).
(D) viSNE profiles using CytoBank show that LAG-3 and PD-1 defined several overlapping populations of CD8+ TILs. The three CD8+ islands (i–iii) that were most
brightly stained islands with anti-LAG-3 (upper panel) were also stained with anti-PD-1 (lower panel). TILs from mice treated with SB415286 showed reduced
expression of LAG-3 on each of the three islands.
(A) Data shown from one individual experiment, representative of two independent experiments. (B) Represents two pooled experiments. Groups are compared
using unpaired t test. *p < 0.05, **p < 0.01, ***p < 0.001. Data are represented as mean ± SEM.Lastly, an examination of TILs showed that both LAG-3 and
PD-1 on TILs were downregulated in this in vivo model (Fig-
ure 3C). Further analysis by CytoBank showed that anti-LAG-3
and PD-1 defined several overlapping populations of CD8+
TILs (Figure 3D). Interestingly, the three CD8+ islands (i–iii) that
were the most brightly stained islands with anti-LAG-3 (upper
panel) were also stained with anti-PD-1 (lower panel). TILs
frommice treated with SB415286 showed a reduced expression
of LAG-3 on each of the three islands. These data showed that
three subpopulations of cells expressing LAG3 and PD-1 were
affected by SB415286.
GSK-3 Downregulation or Inhibition Blocks LAG-3
Transcription
We have previously shown that inhibition of GSK-3 led to an in-
crease in the transcription of Tbx21 (encodes T-box transcriptionfactor Tbet), which was inversely correlated with Pdcd1 tran-
scription (Taylor et al., 2016). We therefore examined whether
the upregulation of Tbet due to GSK-3 inhibition was also con-
nected to the downregulation of LAG-3. Mice were subjected
to B16 melanoma and treated with, or without, SB415286.
CD8+ T cells were isolated from spleens harvested on day 19,
and RT-PCR was performed (Figure 4A). Concurrent with the
preceding findings, LAG-3 expression was reduced by the pres-
ence of SB415286. Furthermore, this was associated with an in-
crease in Tbx21 transcription. Chromatin immunoprecipitation
(ChIP) with anti-Tbet Ab followed by RT-PCR confirmed that
GSK-3 inhibition increased Tbet binding to the LAG-3 promoter
in anti-CD3-activated primary T cells (Figure 4B).
We next examined whether GSK-3 mediated its effect
on LAG-3 transcription via Tbet. OT-I CD8+ T cells were trans-
fected with either scrambled (Scrm) or Tbet siRNA (Figure 4C).Cell Reports 30, 2075–2082, February 18, 2020 2079
Figure 4. Inhibition of GSK-3 Inhibits LAG-3
and Increases Tbx21 Transcription
(A) Tbx21 and LAG-3 transcription in response to
B16 melanoma with or without SB415286 treat-
ment.
(B) ChIP performed using CD3-activated primary
T cells with or without SB415286. ChIP performed
using anti-Tbet Ab followed by PCR analysis of
LAG-3.
(C) Tbet siRNA used to block Tbx21 transcription.
(D) Flow cytometry of LAG-3 expression on T cells
expressing Scrm siRNA or Tbet siRNA in the
presence or absence of SB415286.
(E) CTL killing efficiency of Tbet siRNA-expressing
CTLs in the presence of anti-LAG-3 blockade or
SB415286.
Statistical analysis based on triplicate values in
individual experiments showing means and SDs
(unpaired t test). *p < 0.05, **p < 0.01, ***p < 0.001.Tbet siRNA expression decreased Tbet transcripts while
increasing LAG-3 transcription, a result consistent with the nega-
tive regulation of LAG-3 by Tbet (Durham et al., 2014; Graydon
et al., 2019; Kao et al., 2011). Importantly, SB415286 failed to
reduce LAG-3 expression in cells expressing Tbet siRNA, as as-
sessed by flow cytometry (Figure 4D). Tbet siRNA impaired CTL
killing over different E:T ratios (Figure 4E). This inhibition was
partially restored by LAG-3 blockade; however, GSK-3 inhibition
had no effect. This result indicated that the modulatory effects of
GSK-3 on LAG-3 expression operated in a pathway that required
the expression of Tbet.
Overall, our findings demonstrating GSK-3 regulation of
LAG-3 expression introduce a new pathway in the regulation
of T cell responses in cancer immunotherapy. We have shown
that GSK-3 now targets the two central IRs that are linked to
T cell non-responsiveness or exhaustion (McLane et al., 2019;
Wherry, 2011). Anti-PD-1 therapy, although effective, gener-
ates residual CD8+ T cells expressing PD-1+LAG-3+ T cells
with an exhaustion phenotype (Wei et al., 2019). GSK-3
SMIs, by reducing the expression of both PD-1 and LAG3,
should promote the functionality of T cells in tumors, either
in the context of anti-PD-1 or LAG-3 immunotherapy. Future
studies will assess whether the GSK-3-PD1/LAG3 axis also
affects other key players like the transcription factor TOX in
determining the response of intra-tumoral T-cells (Alfei et al.,
2019). Importantly, our findings showed that the combination
of anti-LAG-3 with GSK-3 inactivation was as effective as,
or more effective than, anti-LAG-3 and anti-PD-1 in B16 mel-
anoma cancer therapy. The synergic effect of LAG-3 with2080 Cell Reports 30, 2075–2082, February 18, 2020PD-1 blockade has been studied extensively (Woo et al.,
2012). One advantage of our approach in targeting GSK-3 in-
volves the potential oral use of SMIs, which could be used in
combination with anti-LAG-3. Intriguingly, in this context, we
found that the combination of anti-LAG-3 plus SB415286
was more effective in the complete clearance of tumor
mass than the combination of anti-LAG-3 and anti-PD-1. Its
ability to compliment anti-LAG-3 presumably results
from the limited effectiveness of Ab blockade in maintaining
the complete blockade of receptors in vivo, as well as its
ability to increase the expression of Tbet (Taylor et al.,
2016), a key transcription factor for the development of
CTLs and the transcription of granzymes and interferon-g1
(Glimcher, 2007). Overall, our findings show that GSK-3
inactivation can potentiate the anti-tumor effects of anti-
LAG-3 even more effectively than the combination anti-
LAG-3 and PD-1 to eliminate tumor cells.STAR+METHODS
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anti-PD-1 (CD279, J43) BioXCell Cat# BE0033-2, RRID:AB_1107747
anti-LAG-3 (C9B7W) BioXCell Cat# BE0174, RRID:AB_10949602
PD-L1 (E1L3N) Cell Signaling Technology Cat# 13684, RRID:AB_2687655
PE anti-human/mouse Granzyme B Recombinant Antibody Biolegend Cat# 372208, RRID:AB_2687032
PE/Cy7 anti-T-bet Antibody Biolegend Cat# 644824, RRID:AB_2561761
PE anti-mouse CD223 (LAG-3) Antibody Biolegend Cat# 125208, RRID:AB_2133343
APC anti-mouse CD279 (PD-1) Antibody Biolegend Cat# 135209
Alexa Fluor(R) 488 anti-mouse CD8a antibody Biolegend Cat# 100723, RRID:AB_389304
PE anti-mouse CD4 antibody Biolegend Cat# 100407, RRID:AB_312692
PE/Cy7 anti-mouse CD335 (NKp46) antibody Biolegend Cat# 137609, RRID:AB_10642684
Chemicals, Peptides, and Recombinant Proteins
SB415286 3-(3-chloro-4-hydroxyphenylamino)-4-(2-
nitrophenyl)-1H-pyrrole-2,5-dione
Abcam plc Cat# ab120962
SB216763 3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-
1H-pyrrole-2,5-dione
Abcam plc Cat# ab120202
CHIR99021 6-[[2-[[4-(2,4-Dichlorophenyl)-5-(5-methyl-1H-
imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-3-
pyridinecarbonitrile
Abcam plc Cat# ab120890
OVA257-264 peptide Bachem Cat# 4053142
OVA Peptide (323-339) GenScript Cat# RP10610
Critical Commercial Assays
CytoTox 96 Non-Radioactive Cytotoxicity Assay Promega Cat# G1780
Pierce Agarose ChIP Kit Thermo Scientific Cat# 26156
RNeasy Mini kit QIAGEN Cat# 74104
TaqMan Reverse Transcription Reagents Applied Biosystems Cat# N808-0234
YBR Green PCR Master Mix Applied Biosystems Cat# 4309155
Experimental Models: Cell Lines
B16-F10-Luc2 (ATCC CRL-6475-LUC2) ATCC Cat# CRL-6475-LUC2
EL4 (ATCC TIB-39) ATCC TIB-39
Experimental Models: Organisms/Strains
Mouse: OT II . C57BL/6-Tg(TcraTcrb)425Cbn/Crl Charles River https://www.criver.com/products-
services/find-model/ot-ii-mouse
Mouse: OT I. C57BL/6-Tg(TcraTcrb)1100Mjb/Crl Charles River https://www.criver.com/products-
services/find-model/ot-i-mouse
Oligonucleotides
LAG-3-FW, 50- CTACAACTCACCGCGTCATTT-30; Thermo Fisher Scientific https://www.thermofisher.com/
LAG-3-RV, 50-GCTCCAGACCCAGAACCTT-30; Thermo Fisher Scientific https://www.thermofisher.com/
GAPDH-FW, 5-CAACAGCAACTCCCACTCTTC-3; Thermo Fisher Scientific https://www.thermofisher.com/
GAPDH- RW, 5- GGTCCAGGGTT TCTTACTCCTT-3 Thermo Fisher Scientific https://www.thermofisher.com/
Tbet-FW, 5-GATCGTCCTGCAGTCTCTCC-3; Thermo Fisher Scientific https://www.thermofisher.com/
Tbet-RW, 5-AACTGTGTTCCCGAGGT GTC-3; Thermo Fisher Scientific https://www.thermofisher.com/
PD-1-FW, 5-CCGCCTTCTGTAATGGTTTGA-3; Thermo Fisher Scientific https://www.thermofisher.com/
PD-1-RV, 5-GGGCAGCTGTATGATCTGGAA-3; Thermo Fisher Scientific https://www.thermofisher.com/
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CTLA-4-FW, 5- ATG GCT TGC CTT GGA TTT CAG-3 Thermo Fisher Scientific https://www.thermofisher.com/
CTLA-4 RW, 5- TCA ATT GAT GGG AAT AAA ATA-3 Thermo Fisher Scientific https://www.thermofisher.com/
Software and Algorithms
Prism GraphPad https://www.graphpad.com/
RRID:SCR_002798
FlowJo BD https://www.flowjo.com/solutions/flowjo
CytExpert Beckman Coulter https://www.mybeckman.uk/LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, A.Taylor
(a.taylor1@leeds.ac.uk). This study did not generate any new unique reagents.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
C57BL/6, PD-1-deficient, OT-I and OT-II Tgmice were bred at the Department of Pathology, University of Cambridge. C57BL/6 were
also bred at St James’s Biomedical Service (SBS) unit, University of Leeds. 8-10 week old female mice were used for all analyses.
Micewere housed in individually ventilated cages (IVC) and all experiments were approved by theHomeOfficeUK (PPLNo. 70/7544).
Primary T cell cultures
Spleen cells (taken from female mice – strains above) were treated with a hypotonic buffer with 0.15M NH4CL, 10mM KHCO3
and 0.1mM EDTA, pH 7.2 to eliminate red blood cells before suspension in RPMI 1640 medium supplemented with 10% FCS,
50uM beta-mercaptoethanol, sodium pyruvate, 2 mM L-glutamine, 100 U/ml penicillin and streptomycin (GIBCO). T cells were iso-
lated from tumor and spleen samples, using T cell purification columns (R&D Systems).
Cell lines
B16F10 melanoma and EL4 lymphoma cells were cultured in DMEMmedium supplemented with 10% FCS, 50uM beta-mercaptoe-
thanol, sodium pyruvate, 2 mM L-glutamine, 100 U/ml penicillin and streptomycin (GIBCO).
METHOD DETAILS
Generation of Cytolytic T cells
OVA specific CD8+ cytoytic T cells (CTLs) were generated by incubating isolated splenocytes OT-I mice with SIINFEKL peptide of
OVA257-264 peptide used at 10nM (Bachem Ag) for 5-7 days.
CTLs were generated in the presence or absence of inhibitors and/or anti-PD-1 or anti-Lag-3 for 5-7 days prior to washing and
analysis by FACs, PCR or in cytoxicity assays. GSK-3 inhibitors were reconstituted in DMSO to give a stock solution of 25mM
and diluted to a concentration of 10uM for in vitro assays.
Activated CD4 T cells
OVA specific CD4+ T cells were generated by incubating isolated splenocytes from OT-II mice with SIINFEKL peptide of OVA323-339
peptide used at 10nM (Bachem Ag) for 5-7 days in the presence or absence of SB415286.
Cytotoxicity Assays
Cytotoxicity was assayed using a Cytotox 96 non-radioactive kit (Promega) following the instructions provided. In brief, purified
T cells were plated in 96-well plates at the effector/target ratios shown using 104 EL4 (pulsed with OVA peptide). Target cells per
well were in a final volume of 200 ml per well using RPMI lacking phenol red. Lactate dehydrogenase release was assayed
after 4 h incubation at 37C by removal of 50 ml supernatant from each well and incubation with substrate provided for 30 min
and the absorbance read at 490 nm using the Thermomax plate reader (Molecular Devices). Percentage cytotoxicity = ((experimental
effectorspontaneous – target spontaneous)/(targetmaximum – target spontaneous)) x 100. All cytotoxicity assays were reproducible
in at least three independent assays.e2 Cell Reports 30, 2075–2082.e1–e4, February 18, 2020
Antibodies and reagents
GSK3 inhibitors used at 10 mM in vitro and 200 mg/mouse in vivo; SB415286, SB216763 and CHIR99021 (Abcam plc). OVA257-264
peptide used at 10nM (Bachem Ag).
Nuclear transfection
In certain cases, naive cells were subjected to nuclear transfection in the presence of various siRNA oligos (i.e., GSK-3). 3.0-5.0ug of
siRNAs were added to 1 3 106 T cells and suspended in 100ul of NucleofectorTM solution for T cells (Amaxa Biosystems, Cologne,
Germany). Cells and oligos were then transferred into a cuvette and electroporated using program X-01 of the NucleofectorTM
(Amaxa Biosystems), and then immediately transferred into pre-warmed RPMI medium.
Flow cytometry
The following antibodies were used in experiments; Anti-CD3 (2C11), anti-PD-1 (CD279, J43) and anti-LAG-3 (C9B7W) (BioXCell);
PD-L1 (E1L3N) (Cell Signaling Technology), conjugated antibodies anti-Granzyme B, anti-Tbet, anti-LAG-3 (C9B7W), CD279
(PD-1), anti-CD8a and anti-CD4 (Biolegend). Flow cytometry of antibody staining of surface receptors was conducted by suspending
106 cells in 100 mL PBS and adding antibody (1:100) for 2hr at 4C. Cells were then washed twice in PBS. Cell staining was analyzed
on a Beckman Coulter Cytoflex S and by CytExpert software. For intracellular staining, cells were fixed in 4% paraformaldehyde
(PFA), permeabilized with 0.3% saponin (Sigma–Aldrich) and stained with the desired antibody in saponin containing PBS for 2hr
at 4C.
Quantitative real-time polymerase chain reaction (PCR)
RNA was isolated using an RNAeasy mini kit (QIAGEN) according to the manufacturer’s instructions. Reverse transcription was
performed to generate cDNA using TaqMan Reverse Transcription Reagents (Applied Biosystems). Quantitative real-time PCR
used SYBR green technology (Applied Biosystems) on cDNA generated from the reverse transcription of purified RNA. After pream-
plification (95C for 2 min), the PCRs were amplified for 40 cycles (95C for 15 s and 60C for 60 s) in a sequence detection
system (PE Prism 7000; Perkin-Elmer Applied Biosystems). The exponential phase, linear phase and plateau phase of PCR ampli-
fication were carefully monitored to ensure a measurement of real time transcription. Data obtained was normalized against GAPDH
expression using the standard curve method.
LAG-3-FW, 50- CTACAACTCACCGCGTCATTT-30;
LAG-3-RV, 50-GCTCCAGACCCAGAACCTT-30;
PD-1-FW, 5-CCGCCTTCTGTAATGGTTTGA-3;
PD-1-RV, 5-GGGCAGCTGTATGATCTGGAA-3;
GAPDH-FW, 5-CAACAGCAACTCCCACTCTTC-3;
GAPDH- RW, 5- GGTCCAGGGTT TCTTACTCCTT-3
CTLA-4-FW, 5- ATG GCT TGC CTT GGA TTT CAG-3
CTLA-4 RW, 5- TCA ATT GAT GGG AAT AAA ATA-3
Tbet-FW, 5-GATCGTCCTGCAGTCTCTCC-3
Tbet-RW, 5-AACTGTGTTCCCGAGGT GTC-3
Chromatin immunoprecipitation (ChIP) assay
C57BL/6 primary T cells were purified using CD3+ T cell enrichment columns, 33 106 cells were used as a resting (input) control while
remaining cells were cultured with anti-CD3 with/without SB415286 for 72h. Chromatin was prepared from all samples (33 106 cells)
and used for ChIP assay following the manufacturers protocols - PierceTM Agarose ChIP kit (Thermo Scientific). Chromatin samples
were immunoprecipitated with antibodies to Tbet, LAG-3, a positive control (anti-RNA polymerase II), or a negative control Rabbit Ig,
both of the latter being provided in the kit. The resulting purified DNAwith bound Abwas then quantified by RT-PCR. The results were
normalized to the non-specific antibody control as well as a standardized aliquot of the input chromatin.
Melanoma lung tumor establishment in wild-type mice
B16 melanoma cells (2 3 105 taken from the log phase of in vitro growth) tagged with luciferase were transferred intravenously into
syngeneic C57BL/6 mice 8-10 weeks old.
Treatment with SB415286 (200 mg/mouse) was given on days 7, 9, 11, 13, 15 and 17 post infection. Anti-LAG-3 (200 mg/mouse)
and/or anti-PD-1 (200 mg/mouse) treatment was given on days 7, 10, 13 and 16.
Live imaging was performed at the time points indicated. Mice were injected intraperitoneally with luciferin (2 ug per mouse),
anaesthetized with isoflurane and scanned with an IVIS Lumina (Caliper Life Sciences). For quantitative comparisons, we used Living
Image software (Caliper Life Sciences) to obtain the maximum radiance (photons per s per cm2 per steradian, i.e., photons
s1 cm2 sr1) over each region of interest, relative to a negative control region. The lungswere excised 19 days after initial transfer.Cell Reports 30, 2075–2082.e1–e4, February 18, 2020 e3
Isolation of tumor infiltrating lymphocytes (TILs)
Lungs were harvested from mice at the time indicated. Tissue was disrupted using a blade and then incubated in HBSS solution
containing 200units/ml of collagenase at 37C for 2 hr. Tissue was then passed through a strainer and cells collected and layered
onto ficoll before centrifugation. Tumor infiltrating cells were then collected from the lymphocyte layer.
QUANTIFICATION AND STATISTICAL ANALYSIS
The mean and SE of each treatment group were calculated for all experiments. The number of samples is indicated in the figure
legends. Unpaired Student’s t tests or ANOVA tests were performed using the InStat 3.0 software (GraphPad). In certain instances,
statistics were done using 2-way ANOVA, or by non-parametric MannWhitney at each time point. * p < 0.05, ** p < 0.01, *** p < 0.001.
DATA AND CODE AVAILABILITY
This study did not generate/analyze datasets/codee4 Cell Reports 30, 2075–2082.e1–e4, February 18, 2020
